Modality
Bispecific Ab
MOA
PRMT5i
Target
CGRP
Pathway
RNA Splicing
PSPPompeNarcolepsy
Development Pipeline
Preclinical
~Jul 2014
→ ~Oct 2015
Phase 1
~Jan 2016
→ ~Apr 2017
Phase 2
~Jul 2017
→ ~Oct 2018
Phase 3
Jan 2019
→ Jul 2030
Phase 3Current
NCT05835696
483 pts·PSP
2020-10→2030-07·Recruiting
NCT03028230
2,266 pts·PSP
2019-07→2025-09·Terminated
NCT06853067
2,819 pts·PSP
2019-01→TBD·Terminated
+1 more trial
7,104 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (3)
2025-09-127mo agoPh3 Readout· PSP
2026-06-273mo awayPh3 Readout· PSP
2030-07-074.3y awayPh3 Readout· PSP
Trial Timeline
2019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3
P3
Termina…
P3
Termina…
P3
Recruit…
P3
Active
Catalysts
Ph3 Readout
2025-09-12 · 7mo ago
PSP
Ph3 Readout
2026-06-27 · 3mo away
PSP
Ph3 Readout
2030-07-07 · 4.3y away
PSP
RecruitingActiveTerminated|StartCompletionToday
Trials (4)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05835696 | Phase 3 | PSP | Recruiting | 483 | DOR |
| NCT03028230 | Phase 3 | PSP | Terminated | 2266 | UPCR |
| NCT06853067 | Phase 3 | PSP | Terminated | 2819 | EASI-75 |
| NCT04339086 | Phase 3 | PSP | Active | 1536 | CR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-6079 | Eli Lilly | Phase 2 | MDM2 | |
| RHH-8550 | Roche | Approved | BCL-2 | |
| RHH-682 | Roche | Phase 2 | FXIa | |
| Talainavolisib | Novo Nordisk | Preclinical | KRASG12D | |
| TAK-9344 | Takeda | Phase 3 | CGRP | |
| AMG-4531 | Amgen | Phase 2/3 | KRASG12C | |
| GIL-9142 | Gilead Sciences | Phase 1 | FXIa | |
| Semainavolisib | Gilead Sciences | Phase 2 | PARP | |
| VRT-1891 | Vertex Pharma | Phase 1 | KRASG12C | |
| Zenotinib | BioNTech | Phase 1 | CGRP |